◆英語タイトル:Theratechnologies Inc (TH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10125
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrifta (tesamorelin for injection) is indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy; and Trogarzo, indicated for the treatment of human immunodeficiency virus type 1 infection in the US. The proprietary technologies of Theratechnologies include long acting peptides, a peptide stabilization technology to increase target protein’s resistance to enzymatic degradation. Theratechnologies is headquartered in Montreal, Quebec, Canada.
Theratechnologies Inc (TH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theratechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 10
Partnerships 12
Grupo Praxis Pharma Enters into Commercialization Agreement with Theratechnologies 12
Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 13
Theratechnologies Enters into Commercialization Agreement with BL&H 14
Licensing Agreements 15
Theratechnologies Enters into Licensing Agreement with AOP Orphan Pharma for Egrifta 15
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 16
Equity Offering 17
Theratechnologies Raises USD12 Million in Private Placement of Shares 17
Theratechnologies Raises USD8.5 Million in Public Offering of Units 19
Debt Offering 20
Theratechnologies Raises USD57.5 Million in Public Offering of 5.75% Notes Due 2023 20
Theratechnologies Inc – Key Competitors 21
Theratechnologies Inc – Key Employees 22
Theratechnologies Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Oct 04, 2018: Theratechnologies announces financial results for the third quarter of 2018 24
Jul 05, 2018: Theratechnologies Announces Financial Results for the Second Quarter of 2018 27
Apr 05, 2018: Theratechnologies Announces Financial Results for First Quarter of 2018 30
Feb 07, 2018: Theratechnologies Announces Financial Results for Fiscal Year 2017 32
Oct 05, 2017: Theratechnologies Announces Financial Results for Third Quarter of 2017 35
Jul 12, 2017: Theratechnologies Announces Financial Results for Second Quarter of 2017 38
Apr 06, 2017: Theratechnologies Announces Financial Results for First Quarter of 2017 41
Feb 08, 2017: Theratechnologies Announces Financial Results for Fiscal Year 2016 44
Corporate Communications 47
Oct 15, 2018: Theratechnologies names New Board Member 47
May 16, 2017: Shareholders elect new Board member during Theratechnologies’ annual meeting 48
Product News 49
07/24/2017: Theratechnologies Announces New Findings with Investigational Antiretroviral EGRIFTA (tesamorelin for injection) 49
03/01/2017: Theratechnologies Holds Investment Community Meeting And Provides Updated Financial Guidance For Its Fiscal Year 2017 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Theratechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theratechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theratechnologies Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 10
Grupo Praxis Pharma Enters into Commercialization Agreement with Theratechnologies 12
Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 13
Theratechnologies Enters into Commercialization Agreement with BL&H 14
Theratechnologies Enters into Licensing Agreement with AOP Orphan Pharma for Egrifta 15
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 16
Theratechnologies Raises USD12 Million in Private Placement of Shares 17
Theratechnologies Raises USD8.5 Million in Public Offering of Units 19
Theratechnologies Raises USD57.5 Million in Public Offering of 5.75% Notes Due 2023 20
Theratechnologies Inc, Key Competitors 21
Theratechnologies Inc, Key Employees 22
Theratechnologies Inc, Subsidiaries 23
List of Figures
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Theratechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8